Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes.
Chantal MathieuDoina CatrinoiuAurelian Emil RanettiEva JohnssonLars HansenHungta ChenRicardo Garcia-SanchezNayyar IqbalAleksander CeliñskiPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2018)
AstraZeneca.